Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Anaplastic Large Cell Lymphoma, ALK-Positive”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 14 of 0 results

Large-scale testing (Phase 3)Looking for participantsNCT05770037
What this trial is testing

DETERMINE Trial Treatment Arm 01: Alectinib in Adult, Paediatric and Teenage/Young Adult Patients With ALK Positive Cancers

Who this might be right for
Haematological MalignancyMalignant NeoplasmLymphoproliferative Disorders+8 more
Cancer Research UK 30
Testing effectiveness (Phase 2)Study completedNCT03505554
What this trial is testing

Oral Lorlatinib in Patients With Relapsed ALK Positive Lymphoma

Who this might be right for
Anaplastic Large Cell Lymphoma, ALK-Positive
University of Milano Bicocca 9
Testing effectiveness (Phase 2)Looking for participantsNCT04925609
What this trial is testing

Brigatinib in Pediatric and Young Adult Patients With ALK+ ALCL, IMT or Other Solid Tumors

Who this might be right for
Anaplastic Large Cell Lymphoma, ALK-PositiveInflammatory Myofibroblastic TumorOther Solid Tumor
Princess Maxima Center for Pediatric Oncology 65
Testing effectiveness (Phase 2)Active Not RecruitingNCT06035497
What this trial is testing

Assess the Safety, Tolerability, Efficacy, and Drug Levels of BMS-986369 (Golcadomide) in Participants With Relapsed or Refractory T-cell Lymphomas in Japan (GOLSEEK-3)

Who this might be right for
Relapsed or Refractory T-cell Lymphomas
Bristol-Myers Squibb 85
Testing effectiveness (Phase 2)Ended earlyNCT04644315
What this trial is testing

A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid Tumors

Who this might be right for
NeoplasmsColorectal NeoplasmsMelanoma+25 more
Hoffmann-La Roche 1
Testing effectiveness (Phase 2)Study completedNCT02419287
What this trial is testing

Pilot Study of Crizotinib in Relapsed ALK+ Lymphomas

Who this might be right for
Anaplastic Large Cell Lymphoma, ALK-Positive
University of Milano Bicocca 12
Not applicableLooking for participantsNCT05978141
What this trial is testing

A Registry for People With T-cell Lymphoma

Who this might be right for
T-cell LymphomaNK-Cell LymphomaT-cell Prolymphocytic Leukemia+28 more
Memorial Sloan Kettering Cancer Center 1,000
Early research (Phase 1)Looking for participantsNCT06176690
What this trial is testing

Constitutive IL7R (C7R) Modified Banked Allogeneic CD30.CAR EBVSTS for CD30-Positive Lymphomas

Who this might be right for
CD30-Positive Diffuse Large B-Cell LymphomaAnaplastic Large Cell Lymphoma, T Cell and Null Cell TypeAnaplastic Large Cell Lymphoma, ALK-Positive+4 more
Baylor College of Medicine 90
Testing effectiveness (Phase 2)WithdrawnNCT03719898
What this trial is testing

Brigatinib in Relapsed or Refractory ALK-Positive Anaplastic Large Cell Lymphoma

Who this might be right for
Anaplastic Large Cell Lymphoma, ALK-Positive
Fox Chase Cancer Center
Early research (Phase 1)Study completedNCT00585195
What this trial is testing

Oral PF-02341066, A C-Met/Hepatocyte Growth Factor Tyrosine Kinase Inhibitor, In Patients With Advanced Cancer

Who this might be right for
Non-Small Cell Lung Cancer ALK-positiveNon-Small Cell Lung Cancer c-Met DependentNon-Small Cell Lung Cancer ROS Marker Positive+2 more
Pfizer 596
Testing effectiveness (Phase 2)UnknownNCT04476459
What this trial is testing

Camrelizumab in Combination With Apatinib in Refractory and Relapsed DLBCL

Who this might be right for
Diffuse Large B Cell LymphomaHigh-grade B-cell LymphomaFollicular Lymphoma Grade IIIb+3 more
Huiqiang Huang 33
Testing effectiveness (Phase 2)Study completedNCT01979536
What this trial is testing

Brentuximab Vedotin or Crizotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II-IV Anaplastic Large Cell Lymphoma

Who this might be right for
Anaplastic Large Cell Lymphoma, ALK-PositiveAnn Arbor Stage II Noncutaneous Childhood Anaplastic Large Cell LymphomaAnn Arbor Stage III Noncutaneous Childhood Anaplastic Large Cell Lymphoma+1 more
National Cancer Institute (NCI) 137
Not applicableNo Longer AvailableNCT05100134
What this trial is testing

Managed Access Programs for LDK378, Ceritinib

Who this might be right for
Anaplastic Lymphoma Kinase (ALK)- Positive TumorsNon-small Cell Lung Cancer (NSCLC)
Novartis Pharmaceuticals
Testing effectiveness (Phase 2)Ended earlyNCT04676360
What this trial is testing

Belantamab Mafodotin In Plasmablastic Lymphoma & ALK+ Large B-Cell Lymphoma

Who this might be right for
Relapsed Plasmablastic LymphomaRefractory Plasmablastic LymphomaAnaplastic Lymphoma Kinase Positive Large B-Cell Lymphoma
Jacob Soumerai, MD 10